Drug-target residence time and its implications for lead optimization
The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Much of drug discovery today is predicated on the concept of selective targeting of particular bioactive macromolecules by low-molecular-mass drugs. The binding of drugs to their macromolecular targets is therefore seen as paramount for pharmacological activity. In vitro assessment of drug-target interactions is classically quantified in terms of binding parameters such as IC(50) or K(d). This article presents an alternative perspective on drug optimization in terms of drug-target binary complex residence time, as quantified by the dissociative half-life of the drug-target binary complex. We describe the potential advantages of long residence time in terms of duration of pharmacological effect and target selectivity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The translation between slow inhibitor binding kinetics and sustained pharmacodynamic modulation has been studied for a numberoftarget classes (58).”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [58]
In the citing paper
“Furthermore, the targets of infectious diseases usually have high replication rates, while covalent inhibitors tend to have long residence times making them less effective in this area [128].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [128]
In the citing paper
“Furthermore, longer residence times of drugs with their targets, as a result of slower off-rates, is a useful mechanism to extend in-vivo efficacy (59–61).”
From A PKA-selective inhibitor captures an open but more ordered conformation of the PKA catalytic subunit (2026) · cites this paper as [59]
Citations
Cites
Catalysis in chemistry and enzymology
Jencks, W. P. (1969) · Medical Entomology and Zoology · Cited by 3,217
Structure and Mechanism in Protein Science
Fersht, A. (1998) · Cited by 1,882
A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)
Wood, E. R., Truesdale, A. T., McDonald, O. B., Yuan, D., Hassell, A., Dickerson, S. H., Ellis, B., Pennisi, C., Horne, E., Lackey, K., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1168 · Cited by 1,122
Copeland, R. A. (2005) · PubMed · Cited by 1,092
Self-citationLiang, J., Woodward, C., & Edelsbrunner, H. (1998) · Protein Science · doi:10.1002/pro.5560070905 · Cited by 1,057
Enzymes: a practical introduction to structure, mechanism, and data analysis
(2001) · Choice Reviews Online · doi:10.5860/choice.38-3881 · Cited by 1,056
Optical biosensors in drug discovery
Cooper, M. A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd838 · Cited by 1,015
Oppenheimer, N. J., & James, T. L. (1989) · Academic Press eBooks · Cited by 820
Rusnak, D. W., Lackey, K. E., Affleck, K., Wood, E. R., Alligood, K. J., Rhodes, N., Keith, B. R., Murray, D. M., Knight, W. B., Mullin, R. J., et al. (2001) · PubMed · Cited by 728
Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis
Copeland, R. A. (2000) · Wiley eBooks · doi:10.1002/0471220639 · Cited by 726
Self-citation
Cited by
Items 601–700 of 1,003
Peptidomimetic Vinyl Heterocyclic Inhibitors of Cruzain Effect Antitrypanosomal Activity
Chenna, B., Li, L., Mellott, D. M., Zhai, X., Siqueira-Neto, J. L., Calvet, C. M., Bernatchez, J. A., Desormeaux, E. K., Hernandez, E. A., Gomez, J., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b02078 · Cited by 27
Self-citationCheong, E. J. Y., Nair, P. C., Neo, R. W. Y., Ho, T. T., Lin, F., Chiong, E., Esuvaranathan, K., Fan, H., Szmulewitz, R. Z., Peer, C. J., et al. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.265868 · Cited by 29
Davis, B. J., & Roughley, S. D. (2017) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2017.07.002 · Cited by 35
Thermodynamic analysis of Jun-Fos coiled coil peptide antagonists: Coiled coils and ITC
Worrall, J. A. R., & Mason, J. M. (2010) · FEBS Journal · doi:10.1111/j.1742-4658.2010.07988.x · Cited by 30
Acchione, M., Lipschultz, C. A., DeSantis, M. E., Shanmuganathan, A., Li, M., Wlodawer, A., Tarasov, S. G., & Smith‐Gill, S. J. (2009) · Molecular Immunology · doi:10.1016/j.molimm.2009.08.018 · Cited by 27
Kinetic Tuning of HDAC Inhibitors Affords Potent Inducers of Progranulin Expression
Moreno-Yruela, C., Fass, D. M., Cheng, C., Herz, J., Olsen, C. A., & Haggarty, S. J. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00281 · Cited by 27
Advances in reversible covalent kinase inhibitors
Zhao, Z., & Bourne, P. E. (2024) · Medicinal Research Reviews · doi:10.1002/med.22084 · Cited by 29
Gebre, S. T., Cameron, S. A., Li, L., Babu, Y. S., & Schramm, V. L. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.801779 · Cited by 26
Multiscale Simulation of Receptor–Drug Association Kinetics: Application to Neuraminidase Inhibitors
Zeller, F., Luitz, M. P., Bomblies, R., & Zacharias, M. (2017) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.7b00631 · Cited by 27
Kong, X., Sun, H., Pan, P., Zhu, F., Chang, S., Xu, L., Li, Y., & Hou, T. (2018) · Physical Chemistry Chemical Physics · doi:10.1039/c7cp08241j · Cited by 26
Discovery of DS-1971a, a Potent, Selective NaV1.7 Inhibitor
Shinozuka, T., Kobayashi, H., Suzuki, S. T., Tanaka, K., Karanjule, N. S., Hayashi, N., Tsuda, T., Tokumaru, E., Inoue, M., Ueda, K., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00259 · Cited by 26
Parallel Discovery Strategies Provide a Basis for Riboswitch Ligand Design
Tran, B., Pichling, P., Tenney, L., Connelly, C. M., Moon, M. H., Ferré-D’Amaré, A. R., Schneekloth, J. S., & Jones, C. P. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.07.021 · Cited by 27
Panknin, O., Wagenfeld, A., Bone, W., Bender, E., Nowak-Reppel, K., Fernandez-Montalvan, A., Nubbemeyer, R., Baurle, S., Ring, S., Schmees, N., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01076 · Cited by 18
The Active Site of a Prototypical “Rigid” Drug Target is Marked by Extensive Conformational Dynamics
Singh, H., Das, C. K., Vasa, S. K., Grohe, K., Schäfer, L. V., & Linser, R. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202009348 · Cited by 26
He, S., Li, L., Jin, R., & Lu, X. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00390 · Cited by 28
Mayer, C. L., Snyder, W. K., Swietlicka, M. A., VanSchoiack, A. D., Austin, C., & McFarland, B. J. (2009) · BMC Research Notes · doi:10.1186/1756-0500-2-135 · Cited by 26
Segala, E., Errey, J. C., Fiez-Vandal, C., Zhukov, A., & Cooke, R. M. (2015) · FEBS Letters · doi:10.1016/j.febslet.2015.04.030 · Cited by 26
Vilums, M., Zweemer, A. J. M., Barmare, F., van der Gracht, A. M. F., Bleeker, D. C. T., Yu, Z., de Vries, H., Gross, R. S., Clemens, J. J., Krenitsky, P. J., et al. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.01.063 · Cited by 26
Kawamura, S., Unno, Y., Asai, A., Arisawa, M., & Shuto, S. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500045x · Cited by 26
Hothersall, J. D., Guo, D. M., Sarda, S., Sheppard, R. J., Chen, H., Keur, W., Waring, M. J., IJzerman, A. P., Hill, S. J., Dale, I. L., et al. (2016) · Molecular Pharmacology · doi:10.1124/mol.116.105551 · Cited by 26
Guo, Z., Wu, F., Singh, V., Guo, T., Ren, X., Yin, X., Shao, Q., York, P., Patterson, L. H., & Zhang, J. (2017) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2017.03.042 · Cited by 26
Wong, C. F. (2018) · Journal of Computational Chemistry · doi:10.1002/jcc.25201 · Cited by 26
KinITC—One Method Supports both Thermodynamic and Kinetic SARs as Exemplified on FimH Antagonists
Zihlmann, P., Silbermann, M., Sharpe, T., Jiang, X., Mühlethaler, T., Jakob, R. P., Rabbani, S., Sager, C. P., Frei, P., Pang, L., et al. (2018) · Chemistry - A European Journal · doi:10.1002/chem.201802599 · Cited by 26
Residence Time Prediction of Type 1 and 2 Kinase Inhibitors from Unbinding Simulations
Braka, A., Garnier, N., Bonnet, P., & Aci‐Sèche, S. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00497 · Cited by 29
Exploiting the Indole Scaffold to Design Compounds Binding to Different Pharmacological Targets
Taliani, S., Settimo, F. D., Martini, C., Laneri, S., Novellino, E., & Greco, G. (2020) · Molecules · doi:10.3390/molecules25102331 · Cited by 27
Martella, A., Sijben, H. J., Rufer, A. C., Grether, U., Fingerle, J., Ullmer, C., Härtung, T., IJzerman, A. P., van der Stelt, M., & Heitman, L. H. (2017) · Molecular Pharmacology · doi:10.1124/mol.117.108605 · Cited by 26
Kinetic Stability of the Streptavidin–Biotin Interaction Enhanced in the Gas Phase
Deng, L., Broom, A., Kitova, E. N., Richards, M. R., Zheng, R. B., Shoemaker, G. K., Meiering, E. M., & Klassen, J. S. (2012) · Journal of the American Chemical Society · doi:10.1021/ja305213z · Cited by 25
Targeting GSK3 from Ustilago maydis: Type-II Kinase Inhibitors as Potential Antifungals
Grütter, C., Simard, J. R., Mayer‐Wrangowski, S. C., Schreier, P. H., Pérez‐Martín, J., Richters, A., Getlik, M., Gutbrod, O., Braun, C. A., Beck, M. E., et al. (2012) · ACS Chemical Biology · doi:10.1021/cb300128b · Cited by 25
Multi-scale modeling of drug binding kinetics to predict drug efficacy
Clarelli, F., Liang, J., Martinecz, A., Heiland, I., & Wiesch, P. A. Z. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03376-y · Cited by 25
Lessons Learnt from COVID-19: Computational Strategies for Facing Present and Future Pandemics
Pavan, M., & Moro, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054401 · Cited by 26
Kosar, M., Sarott, R. C., Sykes, D. A., Viray, A. E. G., Vitale, R. M., Tomašević, N., Li, X., Ganzoni, R. L. Z., Kicin, B., Reichert, L., et al. (2024) · ACS Central Science · doi:10.1021/acscentsci.3c01461 · Cited by 25
Frank, A. T., & Andricioaei, I. (2016) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.6b02654 · Cited by 26
Zeilinger, M., Pichler, F., Nics, L., Wadsak, W., Spreitzer, H., Hacker, M., & Mitterhauser, M. (2017) · EJNMMI Research · doi:10.1186/s13550-016-0249-9 · Cited by 27
Deganutti, G., Zhukov, A., Deflorian, F., Federico, S., Spalluto, G., Cooke, R. M., Moro, S., Mason, J. S., & Bortolato, A. (2017) · In Silico Pharmacology · doi:10.1007/s40203-017-0037-x · Cited by 25
Eaton, J. R. O., Alenazi, Y., Singh, K., Davies, G., Geis‐Asteggiante, L., Kessler, B. M., Robinson, C. V., Kawamura, A., & Bhattacharya, S. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.000487 · Cited by 25
Bernetti, M., Rosini, E., Mollica, L., Masetti, M., Pollegioni, L., Recanatini, M., & Cavalli, A. (2018) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00518 · Cited by 25
Yun, Y., Chen, J., Liu, R., Chen, W., Liu, C., Wang, R., Hou, Z., Yu, Z., Sun, Y., IJzerman, A. P., et al. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.03.032 · Cited by 25
Bosma, R., Stoddart, L. A., Georgi, V., Bouzo-Lorenzo, M., Bushby, N., Inkoom, L., Waring, M. J., Briddon, S. J., Vischer, H. F., Sheppard, R. J., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-44025-5 · Cited by 25
Filipe, H. A. L., Javanainen, M., Salvador, A., Galvão, A. M., Vattulainen, I., Loura, L. M. S., & Moreno, M. J. (2018) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.8b00150 · Cited by 26
Fukasaka, Y., Nambu, H., Tanioka, H., Obata, A., Tonomura, M., Okuno, T., & Yukioka, H. (2018) · Neuropeptides · doi:10.1016/j.npep.2018.05.006 · Cited by 24
Shao, Q., & Zhu, W. (2019) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.9b05226 · Cited by 28
Design and SAR Analysis of Covalent Inhibitors Driven by Hybrid QM/MM Simulations
Lodola, A., Callegari, D., Scalvini, L., Rivara, S., & Mor, M. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0282-9_19 · Cited by 25
Lang, P. A., Leissing, T. M., Page, M. G. P., Schofield, C. J., & Brem, J. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02073-20 · Cited by 26
Long, M. J. C., Rogg, C., & Aye, Y. (2020) · Accounts of Chemical Research · doi:10.1021/acs.accounts.0c00537 · Cited by 26
Inhibition of Na V 1.7: the possibility of ideal analgesics
Kitano, Y., & Shinozuka, T. (2022) · RSC Medicinal Chemistry · doi:10.1039/d2md00081d · Cited by 27
Optimizing molecular potential models by imposing kinetic constraints with path reweighting
Bolhuis, P. G., Brotzakis, Z. F., & Keller, B. G. (2023) · The Journal of Chemical Physics · doi:10.1063/5.0151166 · Cited by 28
Zhou, J., Du, T., Wang, X., Yao, H., Deng, J., Li, Y., Chen, X., Li, S., Ji, M., & Xu, B. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01152 · Cited by 24
Lange, J. H. M., Venhorst, J., van Dongen, M. J. P., Frankena, J., Bassissi, F., de Bruin, N. M. W. J., den Besten, C., de Beer, S. B. A., Oostenbrink, C., Markova, N., et al. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.04.023 · Cited by 24
Chua, H. E., Bhowmick, S. S., & Tucker‐Kellogg, L. (2017) · Methods · doi:10.1016/j.ymeth.2017.05.015 · Cited by 26
Chen, L., Fu, W., Feng, C., Qu, R., Tong, L., Zheng, L., Fang, B., Qiu, Y., Hu, J., Cai, Y., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.08.061 · Cited by 24
KBbox: A Toolbox of Computational Methods for Studying the Kinetics of Molecular Binding
Bruce, N. J., Ganotra, G. K., Richter, S., & Wade, R. C. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00485 · Cited by 24
Lesuisse, D., Mauger, J., Nemecek, C., Maignan, S., Boiziau, J., Harlow, G. R., Hittinger, A., Ruf, S., Strobel, H., Nair, A. C., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.03.003 · Cited by 24
Improved pharmaceutical research and development with AIE-based nanostructures
Zhang, Y., Wang, Y., Wang, J., & Liang, X. (2018) · Materials Horizons · doi:10.1039/c8mh00648b · Cited by 23
Kim, H. S., Hammill, J. T., Scott, D. C., Chen, Y., Rice, A. L., Pistel, W., Singh, B., Schulman, B. A., & Guy, R. K. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00035 · Cited by 23
Cao, X., Wang, P., Zhao, W., Yuan, H., Hu, H.-T., Chen, T., Zhang, Y., Ren, Y., Su, L., Fu, K., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00015 · Cited by 24
Itoh, Y., Zhan, P., Tojo, T., Jaikhan, P., Ota, Y., SUZUKI, M. T., Li, Y., Hui, Z., Moriyama, Y., Takada, Y., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01095 · Cited by 27
Hughes, A. D., McNamara, A., & Steinfeld, T. (2012) · Progress in medicinal chemistry · doi:10.1016/b978-0-12-396493-9.00003-0 · Cited by 23
Smits, R. A., Lim, H. D., van der Meer, T., Kuhne, S., Bessembinder, K., Zuiderveld, O. P., Wijtmans, M., de Esch, I. J. P., & Leurs, R. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.10.104 · Cited by 23
Label-free detection of small-molecule binding to a GPCR in the membrane environment
Heym, R. G., Hornberger, W., Lakics, V., & Terstappen, G. C. (2015) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2015.04.003 · Cited by 23
Andaloussi, M., Lim, H. D., van der Meer, T., Sijm, M., Poulie, C. B. M., de Esch, I. J. P., Leurs, R., & Smits, R. A. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.02.091 · Cited by 23
ElSawy, K. M., Twarock, R., Lane, D. P., Verma, C. S., & Caves, L. S. D. (2011) · Journal of Chemical Theory and Computation · doi:10.1021/ct200560w · Cited by 24
A general method for quantifying ligand binding to unmodified receptors using Gaussia luciferase
Tóth, A. D., Garger, D., Prokop, S., Soltész‐Katona, E., Várnai, P., Balla, A., Turu, G., & Hunyady, L. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100366 · Cited by 24
Sustained wash-resistant receptor activation responses of GPR119 agonists
Hothersall, J. D., Bussey, C. E., Brown, A., Scott, J. S., Dale, I. L., & Rawlins, P. B. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.06.031 · Cited by 23
On the origin of the stereoselective affinity of Nutlin-3 geometrical isomers for the MDM2 protein
ElSawy, K. M., Verma, C. S., Lane, D. P., & Caves, L. S. D. (2013) · Cell Cycle · doi:10.4161/cc.27273 · Cited by 24
Residence Times from Molecular Dynamics Simulations
Sánchez, H. R. (2022) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.2c03756 · Cited by 22
Sabatier, P., Beusch, C. M., Meng, Z., & Zubarev, R. A. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.2c03506 · Cited by 23
Liu, W., Wang, X., Yang, W., Li, X., Qi, D., Chen, H., Liu, H., Yu, S., Pan, Y., Liu, Y., et al. (2022) · Biomolecules · doi:10.3390/biom12121866 · Cited by 22
Xu, C., Zhang, X., Zhao, L., Verkhivker, G. M., & Bai, F. (2024) · JACS Au · doi:10.1021/jacsau.4c00123 · Cited by 26
Vauquelin, G., & Liefde, I. V. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.687720 · Cited by 22
Ye, F. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1020788 · Cited by 22
Vauquelin, G. (2012) · MedChemComm · doi:10.1039/c2md20015e · Cited by 24
Surface Coverage and Competitive Adsorption on Carbon Nanotubes
Fernandes, R. M. F., Buzaglo, M., Regev, O., Marques, E. F., & Furó, I. (2015) · The Journal of Physical Chemistry C · doi:10.1021/acs.jpcc.5b06685 · Cited by 22
Dubbelboer, I. R., Lilienberg, E., Sjögren, E., & Lennernäs, H. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00974 · Cited by 22
You, W., & Chang, C. A. (2018) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.7b00640 · Cited by 22
Advanced analytical methodologies in Alzheimer’s disease drug discovery
Simone, A. D., Naldi, M., Tedesco, D., Bartolini, M., Davani, L., & Andrisano, V. (2019) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2019.112899 · Cited by 22
Luo, Z., Yu, G., Han, X., Yang, T., Ji, Y., Huang, H., Wang, G., Li, X., & Sun, W. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109660 · Cited by 22
Ramesh, J. (2020) · ACS Omega · doi:10.1021/acsomega.9b02663 · Cited by 24
Lee, Y.-J., Song, H., Yoon, Y. J., Park, S.-J., Kim, S., Han, D. C., & Kwon, B. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113920 · Cited by 26
Pedreira, J. G. B., Nahidino, P., Kudolo, M., Pantsar, T., Berger, B., Förster, M., Knapp, S., Laufer, S., & Barreiro, E. J. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00508 · Cited by 22
Meyners, C., Baud, M. G. J., Fuchter, M. J., & Meyer‐Almes, F. (2014) · Analytical Biochemistry · doi:10.1016/j.ab.2014.05.014 · Cited by 23
Active-Learning Exercises to Teach Drug-Receptor Interactions in a Medicinal Chemistry Course
Satyanarayanajois, S. D. (2010) · American Journal of Pharmaceutical Education · doi:10.5688/aj7408147 · Cited by 22
Bosma, R., Wang, Z., Kooistra, A. J., Bushby, N., Kuhne, S., van den Bor, J., Waring, M. J., de Graaf, C., de Esch, I. J. P., Vischer, H. F., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00447 · Cited by 22
Crystal structure of GSK-3B in complex with pyrazine inhibitor C50
Piretti, V., Giabbai, B., Demitri, N., Martino, R. D., Tripathi, S. K., Gobbo, D., Decherchi, S., Storici, P., Girotto, S., & Cavalli, A. (2018) · Worldwide Protein Data Bank · doi:10.2210/pdb6hk7/pdb · Cited by 22
Lipid molecules can induce an opening of membrane-facing tunnels in cytochrome P450 1A2
Jeřábek, P., Florián, J., & Martínek, V. (2016) · Physical Chemistry Chemical Physics · doi:10.1039/c6cp03692a · Cited by 21
Physics of biomolecular recognition and conformational dynamics
Chu, W., Yan, Z., Chu, X., Zheng, X., Liu, Z., Xu, L., Zhang, K., & Wang, J. (2021) · Reports on Progress in Physics · doi:10.1088/1361-6633/ac3800 · Cited by 23
Evolution of Slow-Binding Inhibitors Targeting Histone Deacetylase Isoforms
Mukherjee, A., Zamani, F., & Suzuki, T. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01160 · Cited by 23
Data-driven classification of ligand unbinding pathways
Ray, D., & Parrinello, M. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2313542121 · Cited by 22
Fluctuating Enzyme and Its Biological Functions: Positive Cooperativity without Multiple States
Qian, H., & Shi, P.-Z. (2009) · The Journal of Physical Chemistry B · doi:10.1021/jp810657j · Cited by 21
Link between a high k on for drug binding and a fast clinical action: to be or not to be?
Vauquelin, G. (2018) · MedChemComm · doi:10.1039/c8md00296g · Cited by 23
Kinetic Selection and Relaxation of the Intrinsically Disordered Region of a Protein upon Binding
Tran, D. P., & Kitao, A. (2020) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.9b01203 · Cited by 22
Revisit ligand-receptor interaction at the human vasopressin V2 receptor: A kinetic perspective
Liu, C., Xia, L., Fu, K., Cao, X., Yan, W., Cheng, J., Roux, T., Peletier, L. A., Yin, X., & Guo, D. M. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173157 · Cited by 21
Teng, Y., Lü, X., Xiao, M., Li, Z., Zou, Y., Ren, S., Cheng, Y., Luo, G., & Xiang, H. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112339 · Cited by 21
Li, L., Chen, N., Xia, D., Xu, S., Dai, W., Tong, Y., Wang, L., Jiang, Z., You, Q., & Xu, X. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.03.016 · Cited by 22
Structure-Based Design of A-1293102, a Potent and Selective BCL-XL Inhibitor
Tao, Z., Wang, X., Chen, J., Ingram, J. P., Jin, S. S., Judge, R. A., Kovar, P. J., Park, C., Sun, C. C., Wakefield, B. D., et al. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00162 · Cited by 23
Uitdehaag, J. C. M., Sünnen, C. M., van Doornmalen, A. M., de Rouw, N., Oubrie, A., Azevedo, R., Ziebell, M. R., Nickbarg, E. B., Karstens, W.-J. F., & Ruygrok, S. (2011) · SLAS DISCOVERY · doi:10.1177/1087057111418113 · Cited by 21
Vauquelin, G., Liefde, I. V., & Swinney, D. C. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13445 · Cited by 21
Jin, M., Petronella, B. A., Cooke, A., Kadalbajoo, M., Siu, K., Kleinberg, A., May, E. W., Gokhale, P. C., Schulz, R., Kahler, J., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400160a · Cited by 21
Evaluation of protein–ligand affinity prediction using steered molecular dynamics simulations
Okimoto, N., Suenaga, A., & Taiji, M. (2016) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2016.1251851 · Cited by 23
A two‐state model for the kinetics of competitive radioligand binding
Guo, D. M., Peletier, L. A., Bridge, L., Keur, W., de Vries, H., Zweemer, A. J. M., Heitman, L. H., & IJzerman, A. P. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14184 · Cited by 21
Sun, X., Cheng, J., Wang, X., Tang, Y., Ågren, H., & Tu, Y. (2015) · Scientific Reports · doi:10.1038/srep08066 · Cited by 20
Metadata
- Authors
- Copeland, R. A., Pompliano, D. L., & Meek, T. D.
- Affiliations
- GlaxoSmithKline (United States) (US)
- Corresponding author
- Copeland, Robert A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-08-04
- Volume
- 5
- Issue
- 9
- Pages
- 730-739
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2016408686
- Semantic Scholar
- 362824beb2008831aa65b4eb774e5c8703ff9c71
- Cited by
- 1,464
- References
- 46
- Citations by year
- 2026: 83 · 2025: 64 · 2024: 78 · 2023: 79 · 2022: 81 · 2021: 76 · 2020: 83 · 2019: 88 · 2018: 102 · 2017: 104 · 2016: 96 · 2015: 120 · 2014: 74 · 2013: 88 · 2012: 65
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Interaction Studies and Fluorescence Analysis
- Keywords
- drug-target residence time, lead optimization, drug selectivity, drug-target binding, binding affinity
- MeSH terms
- Binding, Competitive, Pharmaceutical Preparations, Humans, Kinetics, Ligands, Technology, Pharmaceutical, Drug Design, Drug Delivery Systems, Macromolecular Substances
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.